+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using FOXP3 mouse mAb against C2C12(1) Hela(2)Jurkat(3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using FOXP3 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using FOXP3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using FOXP3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using FOXP3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit spinal cord using FOXP3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit cerebellum using FOXP3 mouse mAb with DAB staining.    

  
  

The FOXP3 antibody is a crucial tool in immunology research, targeting the FOXP3 (Forkhead Box P3) protein, a transcription factor primarily expressed in regulatory T cells (Tregs). Discovered in the early 2000s, FOXP3 is a master regulator of Treg development and function, essential for maintaining immune tolerance and preventing autoimmune diseases. Mutations in the FOXP3 gene cause IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked), highlighting its biological significance.

FOXP3 antibodies enable the identification and study of Tregs in both human and murine models. They are widely used in techniques like flow cytometry, immunohistochemistry, and Western blotting to detect FOXP3 expression, quantify Treg populations, or assess their functional status in tissues. These antibodies have advanced research in cancer immunology, autoimmune disorders (e.g., rheumatoid arthritis, type 1 diabetes), and transplantation, where Treg dysregulation plays a key role.

Commercial FOXP3 antibodies vary in specificity, targeting different epitopes (e.g., N-terminal or C-terminal regions) and showing species cross-reactivity differences. Validation is critical, as FOXP3 expression can be transient or heterogeneous in activated T cells. Additionally, FOXP3 antibodies have diagnostic potential, with clinical studies exploring Treg levels as biomarkers for disease progression or therapeutic responses. Their utility continues to grow with the development of Treg-targeted therapies and precision immunology approaches.